Literature DB >> 10908890

Prevalence of AD among whites: a summary by levels of severity.

L X Hy1, D M Keller.   

Abstract

OBJECTIVE: To determine age- and sex-specific AD prevalence rates for whites using each of four severity-based definitions of a case: a person diagnosed as having at least questionable AD, one diagnosed as having at least mild AD, one diagnosed as having moderate or severe AD, and one diagnosed as having severe AD.
METHODS: Data from 21 studies of Europeans and North Americans were pooled.
RESULTS: Empirically, one study, from East Boston, is an outlier. Applied to the US population of 1996, the obtained estimates yield a prevalence of 1.7 to 1.9 million cases, depending on whether the outlier study is excluded or included.
CONCLUSIONS: With disease severity taken into account, estimates of AD prevalence from white populations are more consistent than is usually acknowledged. By including disease severity in the case definition, variations in reported rates are much reduced. The outlier status of the East Boston study appears to result from the use of a definition of AD that differs from that used in the other 20 studies. Alternative explanations of the discrepancy between these estimates and the common estimate of 4 million cases are discussed.

Entities:  

Mesh:

Year:  2000        PMID: 10908890     DOI: 10.1212/wnl.55.2.198

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

Review 1.  Galantamine extended release in Alzheimer's disease: profile report.

Authors:  Dean M Robinson; Greg L Plosker
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 2.  Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review.

Authors:  Michal Harciarek; Krzysztof Jodzio
Journal:  Neuropsychol Rev       Date:  2005-09       Impact factor: 7.444

3.  Identification of dementia: agreement among national survey data, medicare claims, and death certificates.

Authors:  Truls Ostbye; Donald H Taylor; Elizabeth C Clipp; Lynn Van Scoyoc; Brenda L Plassman
Journal:  Health Serv Res       Date:  2008-02       Impact factor: 3.402

4.  Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model.

Authors:  Xu Yue; Melissa Lu; Techie Lancaster; Phillip Cao; Shin-Ichiro Honda; Matthias Staufenbiel; Nobuhiro Harada; Zhenyu Zhong; Yong Shen; Rena Li
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 5.  Can Animal Models Inform on the Relationship between Depression and Alzheimer Disease?

Authors:  Jennifer N K Nyarko; Maa O Quartey; Glen B Baker; Darrell D Mousseau
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

Review 6.  Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.

Authors:  Ben Seltzer
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

7.  Sex- and brain region-specific acceleration of β-amyloidogenesis following behavioral stress in a mouse model of Alzheimer's disease.

Authors:  Latha Devi; Melissa J Alldred; Stephen D Ginsberg; Masuo Ohno
Journal:  Mol Brain       Date:  2010-11-08       Impact factor: 4.041

Review 8.  Estrogen and hippocampal plasticity in rodent models.

Authors:  Michael R Foy; Michel Baudry; Roberta Diaz Brinton; Richard F Thompson
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

Review 9.  Non-feminizing estrogens: a novel neuroprotective therapy.

Authors:  Ashley B Petrone; Joshua W Gatson; James W Simpkins; Miranda N Reed
Journal:  Mol Cell Endocrinol       Date:  2014-01-11       Impact factor: 4.102

10.  Number of children is associated with neuropathology of Alzheimer's disease in women.

Authors:  Michal Schnaider Beeri; Michael Rapp; James Schmeidler; Abraham Reichenberg; Dushyant P Purohit; Daniel P Perl; Hillel T Grossman; Isak Prohovnik; Vahram Haroutunian; Jeremy M Silverman
Journal:  Neurobiol Aging       Date:  2008-01-10       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.